Uveitic macular edema response to intravitreal dexamethasone implant is independent of optical coherence tomography find
- PDF / 341,365 Bytes
- 10 Pages / 547.087 x 737.008 pts Page_size
- 44 Downloads / 167 Views
(0123456789().,-volV) ( 01234567 89().,-volV)
ORIGINAL PAPER
Uveitic macular edema response to intravitreal dexamethasone implant is independent of optical coherence tomography findings Aina Moll-Udina . Marc Figueras-Roca . Joan Oliveres . Anna Sala-Puigdollers Cristina Esquinas . Carmen Alba-Linero . Victor Llorenc¸ . Alfredo Ada´n
.
Received: 17 June 2020 / Accepted: 29 October 2020 Ó Springer Nature B.V. 2020
Abstract Purpose To identify predictive response optical coherence tomography (OCT) findings in uveitic macular edema (UME) treated with intravitreal dexamethasone implant (DEX). Methods Retrospective study of 66 eyes (53 patients) treated with DEX for UME. SD-OCT macular scans were collected prior to DEX treatment and 6 weeks and 3 months after the DEX implant. OCT images were evaluated for qualitative and quantitative characteristics (central retinal thickness, CRT and macular volume, MV). A multivariate analysis of covariance (ANCOVA) was carried out
A. Moll-Udina (&) M. Figueras-Roca A. Sala-Puigdollers C. Alba-Linero V. Llorenc¸ A. Ada´n Hospital Clı´nic, Instituto Clı´nic de Oftalmologia (ICOF), University of Barcelona, Sabino de Arana 1, 08028 Barcelona, Spain e-mail: [email protected] A. Moll-Udina M. Figueras-Roca A. Sala-Puigdollers V. Llorenc¸ A. Ada´n Institut D’Investigacions Biome`diques August Pi I Sunyer (IDIBAPS), Barcelona, Spain J. Oliveres Hospital Vall D’Hebron, Autonomous University of Barcelona, Barcelona, Spain
to study the predictive influence of OCT and clinical covariates on outcomes. The main outcome was a composite endpoint based on the simultaneous gain of 5 or more letters associated with a 20% or more reduction in CRT. Results A significant improvement in BCVA at 6 weeks (mean change from baseline -0.2, SD 0.3) and 3 months (mean -0.2, SD 0.4) was observed after the DEX implant. A significant decrease in CRT (change from baseline -187.7 lm at 3 months) and MV (change from baseline -1.7 mm3 at 3 months) were also observed. An association of C 5-letter improvement in BCVA and a C 20% CRT reduction was observed in 44.6% of cases at 6 weeks and 31.4% at 3 months. ANCOVA multivariate analyses found CRT at 3 months independent from baseline clinical variables but from CRT. Conclusion DEX implant is an effective treatment for UME independently of basal characteristics, producing both a gain of visual acuity and improvement of macular anatomy by OCT measures at 3 months. Keywords Uveitic macular edema Intravitreal dexamethasone implant Optical coherence tomography Uveitis
C. Esquinas Vall Hebron Research Institute, Autonomous University of Barcelona, Barcelona, Spain
123
Int Ophthalmol
Introduction Uveitic macular edema (UME) is a common complication and the most frequent cause of visual loss in uveitis. UME is thought to be caused by the breakdown of blood–retinal barrier and accumulation of fluid within the macula [1–3]. Long-lasting UME may end up in an atrophic retina with irreversible damage and functional impairment [1–3]. Nevertheles
Data Loading...
